This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S). SentiMag® and Sienna+® for sentinel lymph node localisation in breast cancer
. Australia: Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S). Technology Brief. 2014
The current standard-of-care approach for sentinel lymph node (SLN) localisation and biopsy has significant
technical and geographical limitations. It may be possible to overcome these through the use of magnetic technologies such as a hand-held magnetometer and an injectable superparamagnetic iron oxide (SPIO) tracer.
Based on the scant but growing body of evidence for this technology, and its potentially significant potential impact on the investigation of SLN localisation in patients with breast cancer, it is recommended that this technology be monitored for a period of 24 months.
Subject indexing assigned by CRD
Breast Neoplasmss; Contrast Media; Dextrans; Lymph Nodes; Lymphatic Metastasis; Magnetite Nanoparticles; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Technetium Tc 99m Aggregated Albumin
Country of organisation
An English language summary is available.
Address for correspondence
199 Ward Street, North Adelaide SA 5006, Australia. Tel: +61 8 8219 0900, Fax: +61 8 8219 0999 Email: firstname.lastname@example.org
Date abstract record published